Skin and soft-tissue infections requiring hospitalization at an academic medical center: Opportunities for antimicrobial stewardship

Clinical Infectious Diseases

Volumn 51, Issue 8, 2010, Pages 895-903

  Jenkins, Timothy C ^a,b   Sabel, Allison L ^b   Sarcone, Ellen E ^b   Price, Connie S ^a,b   Mehler, Philip S ^b   Burman, William J ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; C REACTIVE PROTEIN; CEFALEXIN; CEFAZOLIN; CLINDAMYCIN; COTRIMOXAZOLE; DICLOXACILLIN; LEVOFLOXACIN; NAFCILLIN; PENICILLIN G; VANCOMYCIN;

ADULT; ALCOHOL ABUSE; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATION; BETA HEMOLYTIC STREPTOCOCCUS; BLOOD CULTURE; CELLULITIS; CLAVISPORA LUSITANIAE; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIABETIC FOOT; DRUG TREATMENT FAILURE; DRUG USE; ENTEROCOCCUS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENSIVE CARE UNIT; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NECROTIZING FASCIITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; PEPTOSTREPTOCOCCUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKIN ABSCESS; TREATMENT DURATION; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ADULT; ANTI-BACTERIAL AGENTS; BACTERIA; BLOOD; COHORT STUDIES; DRUG UTILIZATION; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RECURRENCE; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 77957827875     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/656431     Document Type: Article

References (33)

1. Hersh AL, Chambers HF, Maselli JH, Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med 2008; 168(14):1585-1591.
2. Pallin DJ, Egan DJ, Pelletier AJ, Espinola JA, Hooper DC, Camargo CA Jr. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med 2008; 51(3):291-298.
3. el Moussaoui R, de Borgie CA, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 2006; 332(7554):1355.
4. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG; CAPITAL Study Investigators. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA 2000; 283(6):749-755.
5. McCabe C, Kirchner C, Zhang H, Daley J, Fisman DN. Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. Arch Intern Med 2009; 169(16):1525-1531.
6. Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999; 159(20):2449-2454.
7. Garcia-Vazquez E, Marcos MA, Mensa J, et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch Intern Med 2004; 164(16):1807-1811.
8. Yu H, Greenberg MD, Haviland AM, Farley DO. "Canary measures" among the AHRQ patient safety indicators. Am J Med Qual 2009; 24(6):465-473.
9. Gabow P, Eisert S, Wright R. Denver Health: a model for the integration of a public hospital and community health centers. Ann Intern Med 2003; 138(2):143-149.
10. Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004; 164(15):1669-1674.
11. Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin- resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis 2007; 44(6):777-784.
12. Spellberg B, Talbot GH, Boucher HW, et al. Antimicrobial agents for complicated skin and skin-structure infections: justification of non-inferiority margins in the absence of placebo-controlled trials. Clin Infect Dis 2009; 49(3):383-391.
13. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41(10):1373-1406.
14. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008; 46(11):1683-1693.
15. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49(6):2260-2266.
16. Graham DR, Talan DA, Nichols RL, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin- clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin Infect Dis 2002; 35(4):381-388.
17. Lipsky BA, Weigelt JA, Gupta V, Killian A, Peng MM. Skin, soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes. Infect Control Hosp Epidemiol 2007; 28(11):1290-1298.
18. Carratala J, Roson B, Fernandez-Sabe N, et al. Factors associated with complications and mortality in adult patients hospitalized for infectious cellulitis. Eur J Clin Microbiol Infect Dis 2003; 22(3):151-157.
19. Wong CH, Khin LW, Heng KS, Tan KC, Low CO. The LRINEC (laboratory risk indicator for necrotizing fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med 2004; 32(7):1535-1541.
20. Swartz MN. Clinical practice: cellulitis. N Engl J Med 2004; 350(9):904-912.
21. Schmid MR, Kossmann T, Duewell S. Differentiation of necrotizing fasciitis and cellulitis using MR imaging. AJR Am J Roentgenol 1998; 170(3): 615-620.
22. Blankenship RB, Baker T. Imaging modalities in wounds and superficial skin infections. Emerg Med Clin North Am 2007; 25(1):223-234.
23. Bernard P, Bedane C, Mounier M, Denis F, Catanzano G, Bonnetblanc JM. Streptococcal cause of erysipelas and cellulitis in adults: a microbiologic study using a direct immunofluorescence technique. Arch Dermatol 1989; 125(6):779-782.
24. Eriksson B, Jorup-Ronstrom C, Karkkonen K, Sjoblom AC, Holm SE. Erysipelas: clinical and bacteriologic spectrum and serological aspects. Clin Infect Dis 1996; 23(5):1091-1098.
25. Madaras-Kelly KJ, Remington RE, Oliphant CM, Sloan KL, Bearden DT. Efficacy of oral beta-lactam versus non-beta-lactam treatment of uncomplicated cellulitis. Am J Med 2008; 121(5):419-425.
26. Elliott DJ, Zaoutis TE, Troxel AB, Loh A, Keren R. Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus. Pediatrics 2009; 123(6): e959-e966.
27. Huovinen P. Resistance to trimethoprim-sulfamethoxazole. Clin Infect Dis 2001; 32(11):1608-1614.
28. Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients. ClinicalTrials.gov identifier NCT00676130. http://www.clinicaltrials.gov/ct2/show/ NCT00676130. Accessed 14 June 2010.
29. Strategies Using Off-Patient Antibiotics for Methicillin Resistant S. aureus "STOP MRSA." ClinicalTrials.gov identifier NCT00729937. http://www.clinicaltrials.gov/ct2/show/NCT00729937. Accessed 14 June 2010.
30. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355(7):666-674.
31. Rajendran PM, Young D, Maurer T, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin- resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2007; 51(11):4044-4048.
32. Paydar KZ, Hansen SL, Charlebois ED, Harris HW, Young DM. Inappropriate antibiotic use in soft tissue infections. Arch Surg 2006; 141(9):850-854.
33. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352(14):1436-1444.